MK-677 (ibutamoren) is not an approved medicine in any jurisdiction. This page summarizes side effects documented in its clinical trials and does not constitute medical advice.
Overview
MK-677's most common side effects in human trials were increased appetite, fluid retention (edema and puffiness), transient muscle or joint aches, and lethargy — and, most consequentially, higher fasting blood glucose with reduced insulin sensitivity. The most serious finding came from its hip-fracture recovery trial, which was stopped early after more congestive-heart-failure events in the treated group. Unlike most compounds sold in the same channels, these are not internet anecdotes: MK-677 went through late-stage trials, so its risk profile is documented in peer-reviewed literature — which is exactly how we know development was abandoned for cause.
Common effects seen in trials
Two effects follow directly from the mechanism. Activating the ghrelin ("hunger hormone") receptor produces a marked increase in appetite — the most consistent subjective effect, and the reason MK-677 was studied for wasting rather than weight loss. Raising GH and IGF-1 brings the familiar growth-hormone cluster: water retention, swelling or puffiness, tingling, and joint discomfort.
In the 2-year randomized trial in 65 healthy older adults, the most frequent adverse events on MK-677 were increased appetite that subsided within months, plus transient lower-extremity edema and muscle pain; fasting glucose also rose (Ann Intern Med 2008). Lethargy and drowsiness are commonly reported in community use, consistent with the compound's documented effects on sleep architecture (Neuroendocrinology 1997).
Blood sugar and insulin sensitivity
This is the defining adverse finding, replicated across the program:
Fasting blood glucose increased by about 0.3 mmol/L (roughly 5 mg/dL) and insulin sensitivity declined over a year of 25 mg daily dosing in healthy older adults (Ann Intern Med 2008).
In obese men, an oral glucose tolerance test showed impaired glucose handling at both 2 and 8 weeks of treatment (J Clin Endocrinol Metab 1998).
Even the earliest dose-finding study in healthy elderly subjects recorded a significant rise in fasting glucose at GH-raising doses (J Clin Endocrinol Metab 1996).
GH is a counter-regulatory hormone — it opposes insulin — so this is mechanism, not bad luck, and no studied dose raised GH without it. The signal matters most for people with prediabetes, diabetes, or strong family history, for whom a sustained GH-raising compound pushes in precisely the wrong direction.
The heart-failure signal
A phase IIb trial testing 25 mg daily in 123 elderly patients recovering from hip fracture (62 on MK-677, 61 on placebo) was terminated early over a congestive heart failure safety signal in a limited number of patients; the investigators concluded the safety profile was unfavorable in that population (Arch Gerontol Geriatr 2011).
The honest reading: this occurred in frail, elderly, post-surgical patients, and fluid retention from elevated GH is a plausible contributor. Nobody knows whether the risk extends to young, healthy users — but a sponsor-halted trial is a materially different signal than a rumored side effect, and it ended MK-677's path to approval.
Long-term unknowns and sourcing risks
No trial has followed years of continuous use in healthy adults, so the long-term consequences of sustained IGF-1 elevation — including the theoretical concern of promoting growth of existing malignancies — remain uncharacterized. Everything now sold as MK-677 is gray-market: the FDA has issued warning letters classifying "MK-677 Ibutamoren" products marketed alongside SARMs as unapproved new drugs (FDA, 2023), which means dose accuracy and identity are unverified by anyone. For who tends to be most exposed to compounded and research-chemical risk, see who should avoid using peptides.